Sotrovimab

Sotrovimab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Spike protein of SARS-CoV-2
Clinical data
Trade names	Xevudy
Other names	VIR-7831, GSK4182136
AHFS/Drugs.com	Monograph
MedlinePlus	a621037
License data	US DailyMed: Sotrovimab;
Pregnancy; category	AU: B2;
Routes of; administration	Intravenous
ATC code	J06BD05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; UK: POM (Prescription only); US: ℞-only via emergency use authorization ; EU: Rx-only;
Identifiers
CAS Number	2423014-07-5;
IUPHAR/BPS	11333;
DrugBank	DB16355;
UNII	1MTK0BPN8V;
KEGG	D12014;

Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It was developed by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.

The most common side effects include hypersensitivity (allergic) reactions and infusion-related reactions.

Although Sotrovimab was used world-wide against SARS-CoV-2, including in the United States under an FDA emergency use authorization (EUA), the FDA canceled the EUA in April 2022 due to lack of efficacy against the Omicron variant.